As part of the ongoing monitoring of the Pilot Programme for medicinal cannabis, the Danish Medicines Agency has released a report on the reporting of suspected adverse reactions, cannabis end-products, and the consumption status for 2023.

In 2023, the Danish Medicines Agency received a total of three reports of suspected adverse reactions related to cannabis end-products covered by the Pilot Programme. These reports involve non-serious suspected adverse reactions. The number of such reports per year has decreased by two-thirds in 2023 compared to 2022.

At the same time, the consumption of medicinal cannabis products increased by approximately 72% in 2023, both in terms of the number of patients and the number of prescriptions issued for cannabis end-products under the medicinal cannabis Pilot Programme.

No Safety Concerns Detected

Based on the suspected adverse reaction reports received by the Danish Medicines Agency in 2023, no safety signals regarding cannabis end-products have been identified.

The reports of suspected adverse reactions to cannabis end-products have not prompted the Danish Medicines Agency to implement any risk minimization measures during the period.

For more information, please read the report from the Danish Medicines Agency, "Bivirkningsindberetninger om cannabisslutprodukter og forbrug under forsøgsordningen (pdf)".

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids.

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

For more information, visit: www.dancann.com

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.